A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma

NCT01781572

Last updated date
Study Location
University of California, Dept of Oncology
San Francisco, California, 94101, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Locally Advanced or Metastatic NRAS Mutant Melanoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.

- Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients enrolled into the phase II expansion must have at least one measurable lesion as defined by RECIST 1.1 criteria for solid tumors.

- Patients must have adequate organ function, as defined by the following parameter

1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.

2. Hemoglobin (Hgb) ≥ 9 g/dL.

3. Platelets ≥ 75 x 109/L without transfusions within 21 days before 1st treatment.

4. PT/INR and aPTT ≤ 1.5 ULN.

5. Serum creatinine ≤1.5 ULN.

6. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN).

7. AST and ALT ≤ 3 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ≤ 5 x ULN.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Presence of any brain metastases detected by MRI or CT with i.v. contrast of the brain
at screening.


- Uncontrolled arterial hypertension despite medical treatment


- Impaired cardiac function or clinically significant cardiac diseases, including any of
the following:


1. Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated
acquisition scan (MUGA) or echocardiogram (ECHO).


2. Congenital long QT syndrome or family history of unexpected sudden cardiac death.


3. QTcF corrected with Frederica's or Bazett's formula QTcB >450 ms for males and
>470 ms for females on screening ECG.


4. Angina pectoris ≤ 3 months prior to starting study drug


5. Acute myocardial infarction ≤ 3 months prior to starting study drug


6. Clinically significant resting bradycardia


7. History or presence of ventricular tachyarrhythmia


8. Unstable atrial fibrillation (ventricular response >100 bpm)


9. Complete left bundle branch block


10. Right bundle branch block and left anterior hemi block (bifascicular block)


11. Obligate use of a cardiac pacemaker or implantable cardioverter defibrillator


12. Any other clinically significant heart disease


- Patients who are currently receiving treatment with agents that are known to cause QTc
prolongation in humans.


- Patients who have neuromuscular disorders that are associated with elevated CK (e.g.,
inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal
muscular atrophy) or elevated baseline CK levels (≥ Grade 2)


- Patients who are currently receiving treatment with agents that are metabolized
predominantly through CYP3A4 and that have a narrow therapeutic window.


- Patients with concurrent severe and/or uncontrolled concurrent medical conditions that
could compromise participation in the study (i.e. uncontrolled diabetes mellitus,
clinically significant pulmonary disease, clinically significant neurological
disorder, active or uncontrolled infection).


- History or current evidence of retinal vein occlusion (RVO) or current risk factors
for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity
or hypercoagulability syndromes).


Other protocol related inclusion/exclusion criteria may apply.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Locally Advanced or Metastatic NRAS Mutant MelanomaA Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
NCT01781572
  1. San Francisco, California
  2. San Francisco, California
  3. Detroit, Michigan
  4. New York, New York
  5. New York, New York
  6. Nashville, Tennessee
  7. Houston, Texas
  8. North Sydney, New South Wales
  9. Westmead, New South Wales
  10. East Melbourne, Victoria
  11. Essen,
  12. Gera,
  13. Hannover,
  14. Muenchen,
  15. Napoli,
  16. Utrecht, The Netherlands
  17. Nijmegen,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma
Official Title  ICMJE A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma
Brief Summary In the phase Ib, the primary purpose is to establish the maximum tolerated dose (MTD)(s)/recommended phase ll dose (RP2D) and schedule of LEE011 and MEK162 orally administered combination. Once the MTD(s)/RP2D have been determined for each tested schedule, additional patients will be enrolled in the phase II portion of the study at the RP2D on the chosen schedule in order to assess the anti-tumor activity of the combination in addition to continued evaluation of safety.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Locally Advanced or Metastatic NRAS Mutant Melanoma
Intervention  ICMJE
  • Drug: LEE011
    LEE011 will be administered orally once daily
  • Drug: MEK162
    MEK162 will be administered orally twice daily
Study Arms  ICMJE
  • Experimental: Phase Ib

    The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.

    Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).

    Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).

    Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle).

    Interventions:
    • Drug: LEE011
    • Drug: MEK162
  • Experimental: Phase II

    The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.

    Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination.

    Interventions:
    • Drug: LEE011
    • Drug: MEK162
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 22, 2018)
102
Original Estimated Enrollment  ICMJE
 (submitted: January 30, 2013)
58
Actual Study Completion Date  ICMJE February 20, 2018
Actual Primary Completion Date January 15, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 1.
  • Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients enrolled into the phase II expansion must have at least one measurable lesion as defined by RECIST 1.1 criteria for solid tumors.
  • Patients must have adequate organ function, as defined by the following parameter

    1. Absolute Neutrophil Count (ANC) ? 1.5 x 109/L.
    2. Hemoglobin (Hgb) ? 9 g/dL.
    3. Platelets ? 75 x 109/L without transfusions within 21 days before 1st treatment.
    4. PT/INR and aPTT ? 1.5 ULN.
    5. Serum creatinine ?1.5 ULN.
    6. Serum total bilirubin ? 1.5 x upper limit of normal (ULN).
    7. AST and ALT ? 3 x ULN, except in patients with tumor involvement of the liver who must have AST and ALT ? 5 x ULN.

Exclusion Criteria:

  • Presence of any brain metastases detected by MRI or CT with i.v. contrast of the brain at screening.
  • Uncontrolled arterial hypertension despite medical treatment
  • Impaired cardiac function or clinically significant cardiac diseases, including any of the following:

    1. Left ventricular ejection fraction (LVEF) < 50% as determined by multiple gated acquisition scan (MUGA) or echocardiogram (ECHO).
    2. Congenital long QT syndrome or family history of unexpected sudden cardiac death.
    3. QTcF corrected with Frederica's or Bazett's formula QTcB >450 ms for males and >470 ms for females on screening ECG.
    4. Angina pectoris ? 3 months prior to starting study drug
    5. Acute myocardial infarction ? 3 months prior to starting study drug
    6. Clinically significant resting bradycardia
    7. History or presence of ventricular tachyarrhythmia
    8. Unstable atrial fibrillation (ventricular response >100 bpm)
    9. Complete left bundle branch block
    10. Right bundle branch block and left anterior hemi block (bifascicular block)
    11. Obligate use of a cardiac pacemaker or implantable cardioverter defibrillator
    12. Any other clinically significant heart disease
  • Patients who are currently receiving treatment with agents that are known to cause QTc prolongation in humans.
  • Patients who have neuromuscular disorders that are associated with elevated CK (e.g., inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal muscular atrophy) or elevated baseline CK levels (? Grade 2)
  • Patients who are currently receiving treatment with agents that are metabolized predominantly through CYP3A4 and that have a narrow therapeutic window.
  • Patients with concurrent severe and/or uncontrolled concurrent medical conditions that could compromise participation in the study (i.e. uncontrolled diabetes mellitus, clinically significant pulmonary disease, clinically significant neurological disorder, active or uncontrolled infection).
  • History or current evidence of retinal vein occlusion (RVO) or current risk factors for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity or hypercoagulability syndromes).

Other protocol related inclusion/exclusion criteria may apply.

Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Australia,   Germany,   Italy,   Netherlands,   United States
Removed Location Countries Norway
 
Administrative Information
NCT Number  ICMJE NCT01781572
Other Study ID Numbers  ICMJE CMEK162X2114
C4211005 ( Other Identifier: Pfizer )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date November 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP